-
Something wrong with this record ?
Snášenlivost a účinnost propiverinhydrochloridu u 752 pacientů s příznaky hyperaktivity detruzoru, zvýšené senzitivity a dráždivosti močového měchýře: výsledky studie sledování použití léku
[Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of hyperactivity of the detrusor, increased sensitivity and irritability of the urinary bladder: results of an investigation of the u|se of a drug]
M. Halaška, A. Martan, R. Voigt
Language Czech Country Czech Republic
- MeSH
- Benzilates analogs & derivatives administration & dosage therapeutic use MeSH
- Urinary Incontinence drug therapy MeSH
- Humans MeSH
- Urinary Bladder physiopathology MeSH
- Parasympatholytics administration & dosage adverse effects therapeutic use MeSH
- Urinary Incontinence, Stress drug therapy MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
In a post-marketing surveillance study of 752 patients suffering from urgent incontinence, mixed urgent-stress incontinence, reflex incontinence, urgency and enuresis were treated with propiverine hydrochloride. Clinical efficacy of propiyerine hydrochloride was verified by the improvement of symptoms related to detrusor hyperactivity, hypersensitivity and hyperreflexia miring a 12-week surveillance period: daytime and overnight urinary incontinence, as well as the frequency, nocturia, urgency in day time and at night decreased. These results are well demonstrated by decreased pad use and statistically significant decrease of Gaudenz urgency score during treatment, confirming the efficacy of propiverine hydrochloride already proved in clinical trials. The safety profile of propiverine hydrochloride displayed characteristic anticholinergic symptoms (dry mouth, accommodation disorders, constipation, tiredness, dizziness) with decreasing incidence during the 12-week treatment period. The residual urine volume decreased also. Serious adverse events were observed rarely and could be explained by the lack of consideration of contraindications, warnings and interactions with other drugs. The positive risk-benefit relationship of propiverine hydrochloride in the treatment of detrusor hyperactivity, hypersensitivity and hyperreflexia was reconfirmed in this post-marketing drug surveillance study.
Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of hyperactivity of the detrusor, increased sensitivity and irritability of the urinary bladder: results of an investigation of the u|se of a drug
Snášenlivost a účinnost propiverinhydrochloridu u 752 pacientů s příznaky hyperaktivity detruzoru, zvýšené senzitivity a dráždivosti močového měchýře: výsledky studie sledování použití léku = Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of hyperactivity of the detrusor, increased sensitivity and irritability of the urinary bladder: results of an investigation of the|se of a drug /
Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of hyperactivity of the detrusor, increased sensitivity and irritability of the urinary bladder: results of an investigation of the|se of a drug /
Lit: 28
Bibliography, etc.Souhrn en
- 000
- 00000naa a2200000 a 4500
- 001
- bmc98004130
- 003
- CZ-PrNML
- 005
- 20211101121714.0
- 008
- 971200s1997 xr u cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Halaška, Michael, $d 1947- $4 aut $7 mzk2004258380
- 245 10
- $a Snášenlivost a účinnost propiverinhydrochloridu u 752 pacientů s příznaky hyperaktivity detruzoru, zvýšené senzitivity a dráždivosti močového měchýře: výsledky studie sledování použití léku = $b Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of hyperactivity of the detrusor, increased sensitivity and irritability of the urinary bladder: results of an investigation of the|se of a drug / $c M. Halaška, A. Martan, R. Voigt
- 246 11
- $a Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of hyperactivity of the detrusor, increased sensitivity and irritability of the urinary bladder: results of an investigation of the u|se of a drug
- 314 __
- $a LF UK. VFN. 1. gynekologicko-porodnická klinika, Praha, CZ
- 504 __
- $a Lit: 28
- 504 __
- $a Souhrn en
- 520 9_
- $a In a post-marketing surveillance study of 752 patients suffering from urgent incontinence, mixed urgent-stress incontinence, reflex incontinence, urgency and enuresis were treated with propiverine hydrochloride. Clinical efficacy of propiyerine hydrochloride was verified by the improvement of symptoms related to detrusor hyperactivity, hypersensitivity and hyperreflexia miring a 12-week surveillance period: daytime and overnight urinary incontinence, as well as the frequency, nocturia, urgency in day time and at night decreased. These results are well demonstrated by decreased pad use and statistically significant decrease of Gaudenz urgency score during treatment, confirming the efficacy of propiverine hydrochloride already proved in clinical trials. The safety profile of propiverine hydrochloride displayed characteristic anticholinergic symptoms (dry mouth, accommodation disorders, constipation, tiredness, dizziness) with decreasing incidence during the 12-week treatment period. The residual urine volume decreased also. Serious adverse events were observed rarely and could be explained by the lack of consideration of contraindications, warnings and interactions with other drugs. The positive risk-benefit relationship of propiverine hydrochloride in the treatment of detrusor hyperactivity, hypersensitivity and hyperreflexia was reconfirmed in this post-marketing drug surveillance study.
- 650 _2
- $a močový měchýř $x patofyziologie $7 D001743
- 650 _2
- $a stresová inkontinence moči $x farmakoterapie $7 D014550
- 650 _2
- $a inkontinence moči $x farmakoterapie $7 D014549
- 650 _2
- $a benziláty $x analogy a deriváty $x aplikace a dávkování $x terapeutické užití $7 D001561
- 650 _2
- $a parasympatolytika $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D010276
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 700 1_
- $a Voigt, R. $4 aut
- 700 1_
- $a Kaplan, F. $4 aut
- 700 1_
- $a Rauš, K. $4 aut
- 700 1_
- $a Mašata, Jaromír, $d 1969- $4 aut $7 mzk2004250988
- 700 1_
- $a Klemenc, J. $4 aut
- 700 1_
- $a Martan, Alois, $d 1952- $7 nlk20010103172
- 773 0_
- $w MED00010981 $t Česká gynekologie $g Roč. 62, č. 5 (1997), s. 259-264 $x 1210-7832
- 910 __
- $a ABA008 $b A 4086 $c 310 $y 0 $z 0
- 990 __
- $a 20060528 $b ABA008
- 991 __
- $a 20211101121726 $b ABA008
- BAS __
- $a 3
- BMC __
- $a 1997 $b Roč. 62 $c č. 5 $d s. 259-264 $i 1210-7832 $m Česká gynekologie $x MED00010981
- LZP __
- $b přidání abstraktu